Yuhan Wang, Shuang Wang, Ran Ding, Zequn Zhang, Jing Kong, Tian Xie, Bin Xu, Liming Fu, Erli Zhang
{"title":"Integrated Genomic Analysis of Lung Squamous Cell Carcinoma Subtypes Characterized by Immunogenic Cell Death-Relevant Gene Signature.","authors":"Yuhan Wang, Shuang Wang, Ran Ding, Zequn Zhang, Jing Kong, Tian Xie, Bin Xu, Liming Fu, Erli Zhang","doi":"10.2147/OTT.S503419","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The objective of this study was to identify biomarkers associated with immunogenic cell death (ICD) in lung squamous cell carcinoma (LUSC), focusing on subtypes with distinct immunological characteristics and prognosis. Given the heterogeneous nature of LUSC, understanding ICD's role is crucial for developing tailored therapeutic strategies.</p><p><strong>Patients and methods: </strong>RNA sequencing data from 504 LUSC samples were analyzed using unsupervised clustering to identify ICD-related gene expression patterns. These patterns were linked to immune scores, immune cell infiltration, and clinical outcomes. A separate dataset was used to validate the association between ICD-related subtypes and immunotherapy efficacy.</p><p><strong>Results: </strong>Unsupervised clustering revealed two distinct ICD-related subtypes with significantly different immune scores, immune cell infiltration levels, and prognosis. A prognostic model was developed based on differentially expressed ICD-related genes, which demonstrated strong predictive power for patient survival and immune response. This model may offer valuable insights for clinical decision-making, particularly for immunotherapy strategies.</p><p><strong>Conclusion: </strong>This study identified key ICD-related biomarkers and developed a prognostic model that can enhance our understanding of ICD in LUSC, ultimately guiding personalized treatment approaches.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"18 ","pages":"521-537"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998936/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S503419","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The objective of this study was to identify biomarkers associated with immunogenic cell death (ICD) in lung squamous cell carcinoma (LUSC), focusing on subtypes with distinct immunological characteristics and prognosis. Given the heterogeneous nature of LUSC, understanding ICD's role is crucial for developing tailored therapeutic strategies.
Patients and methods: RNA sequencing data from 504 LUSC samples were analyzed using unsupervised clustering to identify ICD-related gene expression patterns. These patterns were linked to immune scores, immune cell infiltration, and clinical outcomes. A separate dataset was used to validate the association between ICD-related subtypes and immunotherapy efficacy.
Results: Unsupervised clustering revealed two distinct ICD-related subtypes with significantly different immune scores, immune cell infiltration levels, and prognosis. A prognostic model was developed based on differentially expressed ICD-related genes, which demonstrated strong predictive power for patient survival and immune response. This model may offer valuable insights for clinical decision-making, particularly for immunotherapy strategies.
Conclusion: This study identified key ICD-related biomarkers and developed a prognostic model that can enhance our understanding of ICD in LUSC, ultimately guiding personalized treatment approaches.
期刊介绍：
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.
The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.
Specific topics covered by the journal include:
-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials
Further considerations when submitting to OncoTargets and Therapy:
-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
